Eagle Pharmaceutical (EGRX) 38.68 $EGRX
Eagle Pharmaceuticals Down on CRL for Kangio from FDA
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 4:12PM CDT
Eagle Pharmaceuticals (EGRX) announced that it has received a CRL for its blood clot preventing drug, Kangio, from the FDA.
MDCO: 31.31 (-0.17), HZNP: 16.02 (-0.30), EGRX: 38.68 (-2.75), ANIK: 44.00 (-0.74)
Here’s Why Eagle Pharmaceuticals (EGRX) Stock Plunged Today
at The Street - Fri Mar 18, 3:24PM CDT
Eagle Pharmaceuticals (EGRX) stock closed down on heavy trading volume Friday after the FDA rejected its new drug application for its blood thinner drug Kangio.
EGRX: 38.68 (-2.75)
Here's Why Eagle Pharmaceuticals' Stock Cratered Today
George Budwell, The Motley Fool - Motley Fool - Fri Mar 18, 2:54PM CDT
Source: Flickr via user zhouxuan12345678. What : As of 12:10 p.m. EST, Eagle Pharmaceuticals ' stock was down by more than 20% on higher-than-normal volume. The catalyst driving the drugmaker's shares lower today was the news that the U.S. Food...
MDC: 23.79 (+0.38), EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals (EGRX) Stock Tumbles, FDA Rejects Blood Thinner Drug
at The Street - Fri Mar 18, 11:17AM CDT
Eagle Pharmaceuticals (EGRX) stock is sinking on Friday afternoon as the FDA rejected the company’s drug Kangio, which prevents blood clots in some patients undergoing heart surgery.
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals Receives Complete Response Letter from FDA on KANGIO (RTU bivalirudin) Application
Business Wire - Fri Mar 18, 5:50AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) ("Eagle" or the "Company"
today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO(TM) (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use ("RTU" , stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial intended for use as an anticoagulant in patients: (1) undergoing percutaneous coronary intervention ("PCI" with use of glycoprotein IIb/IIIa inhibitor, (2) undergoing PCI with, or at risk of, heparin-induced thrombocytopenia ("HIT" and thrombosis syndrome ("HITTS" , and/or (3) with unstable angina undergoing percutaneous transluminal coronary angioplasty ("PTCA" .
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals to Present at RBC Capital Markets 2016 Global Healthcare Conference
Business Wire - Wed Feb 10, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company" (NASDAQ:EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference as follows:
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 25, 2016
Business Wire - Fri Feb 05, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company" (Nasdaq: EGRX) ("Eagle" announced today that the Company will release its 2015 fourth quarter and full year financial results on Thursday, February 25, 2016, before the market opens.
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals elects Michael Moran as US head of Sales
M2 - Fri Feb 05, 5:02AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) revealed on Thursday the appointment of Michael Moran as US head of Sales with immediate effect.
EGRX: 38.68 (-2.75), GSK: 39.56 (+0.19)
Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales
Business Wire - Thu Feb 04, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company" (NASDAQ:EGRX) today announced that it has appointed Michael Moran, a seasoned sales executive in the pharmaceuticals industry, to the role of U.S. Head of Sales, effective immediately.
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals reports commercial launch of Non-Alcohol Docetaxel Injection in the US
M2 - Wed Feb 03, 3:45AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) reported on Tuesday the shipment and commercial availability of Alcohol-Free Docetaxel Injection for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer.
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula
Business Wire - Tue Feb 02, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company" (NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection ("Docetaxel Injection" . Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
EGRX: 38.68 (-2.75)
FDA Grants Fast Track Designation to RYANODEX for Treatment of Exertional Heat Stroke; Fast Track Designation Highlights Serious, Unmet Medical Need that Exists for Patients with EHS
Business Wire - Mon Feb 01, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company" (NASDAQ:EGRX) today announced that the U.S. Food and Drug Administration ("FDA" has granted Fast Track designation to its RYANODEX(R) (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke ("EHS" , an investigational new indication for the product.
EGRX: 38.68 (-2.75)
Teva & Eagle Pharmaceuticals partnership unveils Injection for CLL & NHL patients
M2 - Fri Jan 29, 4:09AM CST
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA)(TASE:TEVA) and Eagle Pharmaceuticals (Nasdaq:EGRX) jointly reported on Thursday the commercial launch of BENDEKA for treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
TEVA: 54.29 (+0.24), EGRX: 38.68 (-2.75)
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA(TM) (bendamustine hydrochloride) Injection
Business Wire - Thu Jan 28, 10:16AM CST
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced today the commercial availability of BENDEKA(TM), (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.
TEVA: 54.29 (+0.24), EGRX: 38.68 (-2.75)
Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malignant Mesothelioma Overview - Therapeutics Development - Pipeline Products for Malignant Mesothelioma - Overview - Pipeline Products for Malignant Mesothelioma - Comparative Analysis - Malignant Mesothelioma - Therapeutics under Development by Companies - Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes - Malignant Mesothelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malignant Mesothelioma - Products under Development by Companies - Malignant Mesothelioma - Products under Investigation by Universities/Institutes - Malignant Mesothelioma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Berg LLC - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Synta Pharmaceuticals Corp. - Targovax AS - TRACON Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2dt2rm/malignant
ADRO: 12.12 (-0.35), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), BMY: 62.52 (+0.18), EGRX: 38.68 (-2.75), GSK: 39.56 (+0.19), SNTA: 0.24 (-0.01), MRK: 53.07 (-0.01), AVEO: 0.95 (unch), TCON: 6.58 (-0.70), NVS: 73.30 (-0.61), FPRX: 37.31 (+1.73)
Best Small-Cap Stocks of 2015
Beth McKenna, The Motley Fool - Motley Fool - Tue Jan 12, 7:00AM CST
While the overall stock market was flat in 2015, there were some huge winners, especially among smaller company stocks. That's because it's easier for such companies to grow revenue and earnings faster on a percentage basis than it is for larger...
NHTC: 32.02 (-0.73), NPTN: 12.77 (-0.04), TEVA: 54.29 (+0.24), EGRX: 38.68 (-2.75), EXEL: 4.04 (+0.07)
Eagle Pharmaceuticals partners with AMRI to develop, manufacture and commercialise parenteral drug products
M2 - Tue Jan 12, 4:08AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) reported on Monday that it has entered into an agreement to jointly develop and manufacture several select and complex parenteral drug products for registration and subsequent commercialisation in the US in partnership with AMRI (NasdaqGS:AMRI).
EGRX: 38.68 (-2.75), AMRI: 14.03 (-0.04)
Industry Veteran Sherry Korczynski Joins Eagle Pharmaceuticals as Senior Vice President of Marketing
Business Wire - Mon Jan 11, 5:51AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company" (Nasdaq: EGRX) announced today that Sherry Korczynski, a pharmaceutical industry veteran with more than 20 years of experience, will join Eagle as Senior Vice President of Marketing effective immediately.
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals and AMRI Announce Agreement to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products
Business Wire - Mon Jan 11, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company" (NASDAQ:EGRX) and AMRI (NASDAQ:AMRI) today announced that they have entered into an agreement to jointly develop and manufacture several select and complex parenteral drug products for registration and subsequent commercialization in the United States, which will significantly expand Eagle's portfolio of existing products and product candidates targeting therapeutic areas including oncology, critical care and orphan diseases.
EGRX: 38.68 (-2.75), AMRI: 14.03 (-0.04)
AMRI Announces First Product Approval Out of its Massachusetts Aseptic Fill Finish Site
PR Newswire - Mon Jan 11, 5:45AM CST
AMRI (NASDAQ: AMRI) announced that Docetaxel Injection (non-alcohol formula) has been approved for commercial manufacture at its Burlington, Mass. aseptic fill-and-finish facility following U.S. Food and Drug Administration's (FDA) pre-approval inspection for this drug product.
EGRX: 38.68 (-2.75), AMRI: 14.03 (-0.04)
Eagle Pharmaceuticals Down on CRL for Kangio from FDA
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 4:12PM CDT
Eagle Pharmaceuticals (EGRX) announced that it has received a CRL for its blood clot preventing drug, Kangio, from the FDA.
MDCO: 31.31 (-0.17), HZNP: 16.02 (-0.30), EGRX: 38.68 (-2.75), ANIK: 44.00 (-0.74)
Here’s Why Eagle Pharmaceuticals (EGRX) Stock Plunged Today
at The Street - Fri Mar 18, 3:24PM CDT
Eagle Pharmaceuticals (EGRX) stock closed down on heavy trading volume Friday after the FDA rejected its new drug application for its blood thinner drug Kangio.
EGRX: 38.68 (-2.75)
Here's Why Eagle Pharmaceuticals' Stock Cratered Today
George Budwell, The Motley Fool - Motley Fool - Fri Mar 18, 2:54PM CDT
Source: Flickr via user zhouxuan12345678. What : As of 12:10 p.m. EST, Eagle Pharmaceuticals ' stock was down by more than 20% on higher-than-normal volume. The catalyst driving the drugmaker's shares lower today was the news that the U.S. Food...
MDC: 23.79 (+0.38), EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals (EGRX) Stock Tumbles, FDA Rejects Blood Thinner Drug
at The Street - Fri Mar 18, 11:17AM CDT
Eagle Pharmaceuticals (EGRX) stock is sinking on Friday afternoon as the FDA rejected the company’s drug Kangio, which prevents blood clots in some patients undergoing heart surgery.
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals Receives Complete Response Letter from FDA on KANGIO (RTU bivalirudin) Application
Business Wire - Fri Mar 18, 5:50AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) ("Eagle" or the "Company"
today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO(TM) (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use ("RTU" , stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial intended for use as an anticoagulant in patients: (1) undergoing percutaneous coronary intervention ("PCI" with use of glycoprotein IIb/IIIa inhibitor, (2) undergoing PCI with, or at risk of, heparin-induced thrombocytopenia ("HIT" and thrombosis syndrome ("HITTS" , and/or (3) with unstable angina undergoing percutaneous transluminal coronary angioplasty ("PTCA" . EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals to Present at RBC Capital Markets 2016 Global Healthcare Conference
Business Wire - Wed Feb 10, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company"
(NASDAQ:EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference as follows: EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 25, 2016
Business Wire - Fri Feb 05, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"
(Nasdaq: EGRX) ("Eagle" announced today that the Company will release its 2015 fourth quarter and full year financial results on Thursday, February 25, 2016, before the market opens. EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals elects Michael Moran as US head of Sales
M2 - Fri Feb 05, 5:02AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) revealed on Thursday the appointment of Michael Moran as US head of Sales with immediate effect.
EGRX: 38.68 (-2.75), GSK: 39.56 (+0.19)
Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales
Business Wire - Thu Feb 04, 5:50AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"
(NASDAQ:EGRX) today announced that it has appointed Michael Moran, a seasoned sales executive in the pharmaceuticals industry, to the role of U.S. Head of Sales, effective immediately. EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals reports commercial launch of Non-Alcohol Docetaxel Injection in the US
M2 - Wed Feb 03, 3:45AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) reported on Tuesday the shipment and commercial availability of Alcohol-Free Docetaxel Injection for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer.
EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula
Business Wire - Tue Feb 02, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company"
(NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection ("Docetaxel Injection" . Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. EGRX: 38.68 (-2.75)
FDA Grants Fast Track Designation to RYANODEX for Treatment of Exertional Heat Stroke; Fast Track Designation Highlights Serious, Unmet Medical Need that Exists for Patients with EHS
Business Wire - Mon Feb 01, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company"
(NASDAQ:EGRX) today announced that the U.S. Food and Drug Administration ("FDA" has granted Fast Track designation to its RYANODEX(R) (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke ("EHS" , an investigational new indication for the product. EGRX: 38.68 (-2.75)
Teva & Eagle Pharmaceuticals partnership unveils Injection for CLL & NHL patients
M2 - Fri Jan 29, 4:09AM CST
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA)(TASE:TEVA) and Eagle Pharmaceuticals (Nasdaq:EGRX) jointly reported on Thursday the commercial launch of BENDEKA for treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
TEVA: 54.29 (+0.24), EGRX: 38.68 (-2.75)
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA(TM) (bendamustine hydrochloride) Injection
Business Wire - Thu Jan 28, 10:16AM CST
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced today the commercial availability of BENDEKA(TM), (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.
TEVA: 54.29 (+0.24), EGRX: 38.68 (-2.75)
Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Malignant Mesothelioma Overview - Therapeutics Development - Pipeline Products for Malignant Mesothelioma - Overview - Pipeline Products for Malignant Mesothelioma - Comparative Analysis - Malignant Mesothelioma - Therapeutics under Development by Companies - Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes - Malignant Mesothelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Malignant Mesothelioma - Products under Development by Companies - Malignant Mesothelioma - Products under Investigation by Universities/Institutes - Malignant Mesothelioma - Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Aeolus Pharmaceuticals, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Berg LLC - Biogen, Inc. - Bionomics Limited - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Eagle Pharmaceuticals, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Synta Pharmaceuticals Corp. - Targovax AS - TRACON Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2dt2rm/malignant
ADRO: 12.12 (-0.35), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), BMY: 62.52 (+0.18), EGRX: 38.68 (-2.75), GSK: 39.56 (+0.19), SNTA: 0.24 (-0.01), MRK: 53.07 (-0.01), AVEO: 0.95 (unch), TCON: 6.58 (-0.70), NVS: 73.30 (-0.61), FPRX: 37.31 (+1.73)
Best Small-Cap Stocks of 2015
Beth McKenna, The Motley Fool - Motley Fool - Tue Jan 12, 7:00AM CST
While the overall stock market was flat in 2015, there were some huge winners, especially among smaller company stocks. That's because it's easier for such companies to grow revenue and earnings faster on a percentage basis than it is for larger...
NHTC: 32.02 (-0.73), NPTN: 12.77 (-0.04), TEVA: 54.29 (+0.24), EGRX: 38.68 (-2.75), EXEL: 4.04 (+0.07)
Eagle Pharmaceuticals partners with AMRI to develop, manufacture and commercialise parenteral drug products
M2 - Tue Jan 12, 4:08AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) reported on Monday that it has entered into an agreement to jointly develop and manufacture several select and complex parenteral drug products for registration and subsequent commercialisation in the US in partnership with AMRI (NasdaqGS:AMRI).
EGRX: 38.68 (-2.75), AMRI: 14.03 (-0.04)
Industry Veteran Sherry Korczynski Joins Eagle Pharmaceuticals as Senior Vice President of Marketing
Business Wire - Mon Jan 11, 5:51AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company"
(Nasdaq: EGRX) announced today that Sherry Korczynski, a pharmaceutical industry veteran with more than 20 years of experience, will join Eagle as Senior Vice President of Marketing effective immediately. EGRX: 38.68 (-2.75)
Eagle Pharmaceuticals and AMRI Announce Agreement to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products
Business Wire - Mon Jan 11, 5:50AM CST
Eagle Pharmaceuticals ("Eagle" or the "Company"
(NASDAQ:EGRX) and AMRI (NASDAQ:AMRI) today announced that they have entered into an agreement to jointly develop and manufacture several select and complex parenteral drug products for registration and subsequent commercialization in the United States, which will significantly expand Eagle's portfolio of existing products and product candidates targeting therapeutic areas including oncology, critical care and orphan diseases. EGRX: 38.68 (-2.75), AMRI: 14.03 (-0.04)
AMRI Announces First Product Approval Out of its Massachusetts Aseptic Fill Finish Site
PR Newswire - Mon Jan 11, 5:45AM CST
AMRI (NASDAQ: AMRI) announced that Docetaxel Injection (non-alcohol formula) has been approved for commercial manufacture at its Burlington, Mass. aseptic fill-and-finish facility following U.S. Food and Drug Administration's (FDA) pre-approval inspection for this drug product.
EGRX: 38.68 (-2.75), AMRI: 14.03 (-0.04)
